Hui K Gan

Hui K Gan

UNVERIFIED PROFILE

Are you Hui K Gan?   Register this Author

Register author
Hui K Gan

Hui K Gan

Publications by authors named "Hui K Gan"

Are you Hui K Gan?   Register this Author

65Publications

1760Reads

48Profile Views

Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse.

Eur J Nucl Med Mol Imaging 2020 Feb 5. Epub 2020 Feb 5.

Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-020-04706-0DOI Listing
February 2020

Longitudinal molecular trajectories of diffuse glioma in adults.

Nature 2019 12 20;576(7785):112-120. Epub 2019 Nov 20.

The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-019-1775-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897368PMC
December 2019

Young adults diagnosed with high grade gliomas: Patterns of care, outcomes, and impact on employment.

J Clin Neurosci 2019 Oct 29;68:45-50. Epub 2019 Jul 29.

La Trobe University School of Cancer Medicine, Melbourne, Australia; Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, Australia; Monash Health, Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2019.07.063DOI Listing
October 2019

Current Development of Monoclonal Antibodies in Cancer Therapy.

Recent Results Cancer Res 2020 ;214:1-70

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, VIC, 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-23765-3_1DOI Listing
September 2019

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.

Int J Cancer 2019 08 4;145(3):639-648. Epub 2019 Feb 4.

Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Pierre-Bénite, France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.32132
Publisher Site
http://dx.doi.org/10.1002/ijc.32132DOI Listing
August 2019

BI 853520, a FAK-Simile of Prior FAK Inhibitors?

Target Oncol 2019 02;14(1):39-41

Olivia Newton John Cancer Centre, 145 Studley Rd, Heidelberg, VIC, 3084, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11523-019-00621-z
Publisher Site
http://dx.doi.org/10.1007/s11523-019-00621-zDOI Listing
February 2019

Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients.

Intern Med J 2018 Oct;48(10):1206-1214

Medical Oncology Department, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.14000DOI Listing
October 2018

A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting.

J Clin Neurosci 2018 Oct 29;56:127-130. Epub 2018 Jun 29.

Austin Hospital, Heidelberg, Victoria, Australia; La Trobe University School of Cancer Medicine, Melbourne, Australia; Department of Medicine, University of Melbourne, 145 Studley Road, Heidelberg, Victoria 3084, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2018.06.032DOI Listing
October 2018

Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort.

Head Neck 2018 09 17;40(9):2029-2042. Epub 2018 Apr 17.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.25198DOI Listing
September 2018

Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases.

Curr Opin Pharmacol 2018 08 5;41:114-121. Epub 2018 Jun 5.

Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, LaTrobe University, Melbourne, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14714892183001
Publisher Site
http://dx.doi.org/10.1016/j.coph.2018.05.010DOI Listing
August 2018

Receptor Occupancy Imaging Studies in Oncology Drug Development.

AAPS J 2018 03 8;20(2):43. Epub 2018 Mar 8.

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12248-018-0203-zDOI Listing
March 2018

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.

Nat Rev Clin Oncol 2017 Nov 4;14(11):695-707. Epub 2017 Jul 4.

Austin Health and Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Victoria 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.95DOI Listing
November 2017

and Evaluation of Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy.

Theranostics 2016 25;6(12):2225-2234. Epub 2016 Sep 25.

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia;; School of Cancer Medicine, La Trobe University, Melbourne, Australia;; Department of Medicine, University of Melbourne, Melbourne, Australia;; Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia;; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.16260DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135445PMC
October 2017

Evolution of anti-HER2 therapies for cancer treatment.

Cancer Treat Rev 2017 Sep 6;59:1-21. Epub 2017 Jul 6.

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.06.005DOI Listing
September 2017

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Neuro Oncol 2017 Jul;19(7):965-975

Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of Neurology, Northwestern University, Chicago, Illinois; Department of Neurology, NorthShore University HealthSystem, Evanston, Illinois; Department of Medical Oncology, Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia; School of Cancer Medicine, La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australia; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas; Department of Radiation Oncology, The University of Texas M.D.Anderson Cancer Center, Houston, Texas; AbbVie Inc., North Chicago, Illinois; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570193PMC
July 2017

L-Tyrosine Confers Residualizing Properties to a d-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies.

Mol Imaging 2016 25;15. Epub 2016 Jul 25.

Tumour Targeting Program, Ludwig Institute For Cancer Research and Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1536012116647535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470130PMC
December 2016

Temozolomide-Associated Liver Fibrosis.

J Clin Pharmacol 2016 11;56(11):1448-1449

Department of Medical Oncology, Austin Health, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.753DOI Listing
November 2016

Antibody-mediated delivery of therapeutics for cancer therapy.

Expert Opin Drug Deliv 2016 19;13(3):401-19. Epub 2015 Dec 19.

a Tumour Targeting Laboratory , Olivia Newton-John Cancer Research Institute , Melbourne , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425247.2016.1124854DOI Listing
July 2016

Antibody-Drug Conjugates for Cancer Therapy.

Biomedicines 2016 Jul 11;4(3). Epub 2016 Jul 11.

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia.

View Article

Download full-text PDF

Source
http://www.mdpi.com/2227-9059/4/3/14
Publisher Site
http://dx.doi.org/10.3390/biomedicines4030014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344263PMC
July 2016

Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a.

J Nucl Med 2016 06 3;57(6):974-80. Epub 2016 Mar 3.

Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton-John Cancer Research Institute, Melbourne, Australia Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia Department of Medicine, University of Melbourne, Melbourne, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.115.169839DOI Listing
June 2016

Recurrent glioblastoma: Current patterns of care in an Australian population.

J Clin Neurosci 2016 Feb 6;24:78-82. Epub 2015 Nov 6.

Department of Medical Oncology, Austin Health, 145 Studley Road, Heidelberg, Melbourne, VIC 3084, Australia; Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2015.08.025DOI Listing
February 2016

Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.

Eur J Cancer 2016 Jan 27;52:26-32. Epub 2015 Nov 27.

Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France; Hospices Civils de Lyon, Biostatistics Unit, F-69003, Lyon, France; CNRS UMR 5558, Biometry and Evolutionary Biology Laboratory, Health and Biostatistics Team, Villeurbanne, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.08.025DOI Listing
January 2016

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.

J Clin Neurosci 2015 Dec 13;22(12):1889-94. Epub 2015 Aug 13.

Department of Medical Oncology, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09675868150031
Publisher Site
http://dx.doi.org/10.1016/j.jocn.2015.06.005DOI Listing
December 2015

Management of glioblastoma in Victoria, Australia (2006-2008).

J Clin Neurosci 2015 Sep;22(9):1462-6

Victorian Cancer Registry, Cancer Council Victoria, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2015.03.029DOI Listing
September 2015

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.

J Clin Oncol 2015 Aug 29;33(24):2609-16. Epub 2015 Jun 29.

Marika Ciprotti, Niall C. Tebbutt, Fook-Thean Lee, Sze-Ting Lee, Hui K. Gan, Wendie Hopkins, Fiona E. Scott, Andrew M. Scott, Ludwig Institute for Cancer Research; David C. McKee, Graeme J. O'Keefe, Sylvia J. Gong, Geoffrey Chong, Bridget Chappell, Andrew M. Scott, Austin Health, Melbourne, Australia; Martin W. Brechbiel, National Cancer Institute, Bethesda, MD; Archie N. Tse, Jonathan Greenberg, Daiichi Sankyo Co., Ltd, Parsippany, NJ; Mendel Jansen, Daiichi Sankyo Development Ltd, Gerrards Cross, Buckinghamshire, United Kingdom; Manabu Matsumura, Masakatsu Kotsuma, Rira Watanabe, Daiichi Sankyo Co., Ltd, Tokyo, Japan; Robert A. Beckman, Georgetown University Medical Center and Ralph Venhaus, Ludwig Institute for Cancer Research, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.60.4256
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.60.4256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881374PMC
August 2015

Mistaken identity: granular cell astrocytoma masquerading as histiocytosis of the central nervous system.

J Clin Neurosci 2014 Aug 6;21(8):1457-9. Epub 2014 Feb 6.

Joint Austin-Ludwig Oncology Unit, Level 4 Olivia Newton-John Cancer & Wellness Centre, Austin Hospital, 145 Studley Road, Heidelberg, VIC 3084, Australia; Neurology Unit, Austin Health, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09675868140004
Publisher Site
http://dx.doi.org/10.1016/j.jocn.2013.10.037DOI Listing
August 2014

Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma.

EJNMMI Res 2014 30;4:22. Epub 2014 May 30.

Ludwig Institute for Cancer Research, Austin Health, Melbourne 3084, Australia ; Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne 3084, Australia.

View Article

Download full-text PDF

Source
http://www.ejnmmires.com/content/4/1/22
Publisher Site
http://dx.doi.org/10.1186/s13550-014-0022-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070025PMC
July 2014

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.

FEBS J 2013 Nov 8;280(21):5350-70. Epub 2013 Jul 8.

Tumour Targeting Program, Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/febs.12393DOI Listing
November 2013

Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.

J Clin Oncol 2013 Nov 23;31(31):3957-63. Epub 2013 Sep 23.

Julien Péron, Denis Maillet, and Benoit You, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite; Julien Péron, Hospices Civils de Lyon; Julien Péron and Benoit You, Université de Lyon, Lyon; Julien Péron, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne; Benoit You, EMR UCBL/HCL 3738, Faculté de Médecine Lyon-Sud, Oullins, France; Hui K. Gan, Joint Austin-Ludwig Oncology Unit, Austin Hospital, Melbourne, Victoria, Australia; Eric X. Chen, Princess Margaret Hospital, University Health Network; and Eric X. Chen, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/31/31/3957.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.49.3981
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.49.3981DOI Listing
November 2013

Influence of statistician involvement on reporting of randomized clinical trials in medical oncology.

Anticancer Drugs 2013 Mar;24(3):306-9

Department of Medical Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 69495 Pierre-Bénite, France.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00001813-201303000-000
Publisher Site
http://dx.doi.org/10.1097/CAD.0b013e32835c3561DOI Listing
March 2013

Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review.

J Natl Cancer Inst 2012 Jul 3;104(13):982-9. Epub 2012 Jul 3.

Service d'Oncologie Médicale, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 chemin du grand Revoyet, Pierre-Bénite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djs259DOI Listing
July 2012

Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.

J Natl Cancer Inst 2012 Apr 6;104(8):590-8. Epub 2012 Apr 6.

Joint Austin-Ludwig Medical Oncology Unit, Austin Hospital, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djs141DOI Listing
April 2012

Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review.

J Clin Oncol 2012 Jan 12;30(2):210-6. Epub 2011 Dec 12.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, Room 5-719, 610 University Ave, Toronto, Ontario, Canada M5G 2M9.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2011.37.0890
Publisher Site
http://dx.doi.org/10.1200/JCO.2011.37.0890DOI Listing
January 2012

Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland.

Br J Ophthalmol 2011 Nov 22;95(11):1483-9. Epub 2010 Dec 22.

Département d'Oncologie Médicale - Unité d'Investigation Clinique, Institut Curie, 26, rue d'Ulm - 75248 Paris Cedex 05, France.

View Article

Download full-text PDF

Source
http://bjo.bmj.com/cgi/doi/10.1136/bjo.2010.192351
Publisher Site
http://dx.doi.org/10.1136/bjo.2010.192351DOI Listing
November 2011

Antibodies in oncology.

N Biotechnol 2011 Sep 5;28(5):518-29. Epub 2011 Apr 5.

Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbt.2011.03.021DOI Listing
September 2011

Development of anti-cancer drugs.

Discov Med 2010 Oct;10(53):355-62

Clinical Trial Unit, Department of Medical Oncology, Institut Curie, Paris 75248, France.

View Article

Download full-text PDF

Source
October 2010

Randomized phase II trials: inevitable or inadvisable?

J Clin Oncol 2010 May 20;28(15):2641-7. Epub 2010 Apr 20.

Princess Margaret Hospital, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.3343DOI Listing
May 2010

Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab.

Neuro Oncol 2010 Feb 24;12(2):212-5. Epub 2009 Dec 24.

Austin-Ludwig Medical Oncology Department, 145 Stucttey Road, Heidelberg 3084, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nop021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940573PMC
February 2010

Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.

J Clin Oncol 2009 Dec 5;27(35):5965-71. Epub 2009 Oct 5.

Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.22.3685
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.22.3685DOI Listing
December 2009

Low-grade oligodendroglioma: current treatments and future hopes.

Expert Rev Anticancer Ther 2009 Nov;9(11):1651-61

Room 7-702, Princess Margaret Hospital, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.09.127DOI Listing
November 2009

Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization.

J Cell Mol Med 2009 Sep 11;13(9B):3993-4001. Epub 2009 May 11.

Oncogenic Signalling Laboratory, Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1582-4934.2009.00783.x
Publisher Site
http://dx.doi.org/10.1111/j.1582-4934.2009.00783.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516546PMC
September 2009

The EGFRvIII variant in glioblastoma multiforme.

J Clin Neurosci 2009 Jun 25;16(6):748-54. Epub 2009 Mar 25.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2008.12.005DOI Listing
June 2009

Sunitinib in solid tumors.

Expert Opin Investig Drugs 2009 Jun;18(6):821-34

Princess Margaret Hospital, Division of Medical Oncology and Hematology, 610 University Avenue, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543780902980171DOI Listing
June 2009

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.

J Biol Chem 2007 Feb 8;282(5):2840-50. Epub 2006 Nov 8.

Oncogenic Signalling Laboratory, Ludwig Institute of Cancer Research, Austin Hospital, Level 6, Harold Stokes Building, Studley Road, Heidelberg, Victoria 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M605136200DOI Listing
February 2007

A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.

Cancer Chemother Pharmacol 2006 Aug 19;58(2):157-64. Epub 2005 Nov 19.

Department of Medical Oncology and Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-005-0152-y
Publisher Site
http://dx.doi.org/10.1007/s00280-005-0152-yDOI Listing
August 2006